90258-5
LDLR gene full mutation analysis in Blood or Tissue by Sequencing
Active
Part Descriptions
LP150045-5 Sequencing
Sequencing is a method used to determine the sequence of individual genes, larger genetic regions (i.e. clusters of genes or operons), full chromosomes or entire genomes. Historically, most sequencing has been performed using the chain termination method developed by Frederick Sanger in 1977. PMID: 271968 Sequencing technologies have improved dramatically, making them cheaper, faster, and more accurate. Next-generation sequencing (NGS), also known as high-throughput sequencing, deep sequencing, and second-generation sequencing, is a type of technology that uses parallel sequencing of multiple small fragments of DNA to determine sequence. This "high-throughput" technology has increased the speed and amount of DNA sequenced at a significantly reduced cost. PMID: 18576944 Several NGS platforms (ie, sequencing instruments and associated reagents) have been developed. Third-generation sequencing is another methodology currently under development that uses parallel sequencing similar to NGS. In contrast to NGS, third-generation sequencing uses single DNA molecules rather than amplified DNA as a template. PMID: 20858600
Source: Regenstrief LOINC
LP268129-6 LDLR gene full mutation analysis
The LDLR gene (low density lipoprotein receptor) [HGNC Gene ID:6547] is located on chromosome 19p13.2. The low density lipoprotein receptor (LDLR) gene family consists of cell surface proteins involved in receptor-mediated endocytosis of specific ligands. Low density lipoprotein (LDL) is normally bound at the cell membrane and taken into the cell ending up in lysosomes where the protein is degraded and the cholesterol is made available for repression of microsomal enzyme 3-hydroxy-3-methylglutaryl coenzyme A (HMG CoA) reductase, the rate-limiting step in cholesterol synthesis. At the same time, a reciprocal stimulation of cholesterol ester synthesis takes place. Mutations in this gene cause the autosomal dominant disorder, familial hypercholesterolemia. Alternate splicing results in multiple transcript variants.[provided by RefSeq, Sep 2010] [NCBI Gene ID:3949]
Source: National Center for Biotechnology Information (NCBI) Gene
LP95532-5 LDLR gene
The LDLR gene (low density lipoprotein receptor) [HGNC Gene ID:6547] is located on chromosome 19p13.2. The low density lipoprotein receptor (LDLR) gene family consists of cell surface proteins involved in receptor-mediated endocytosis of specific ligands. Low density lipoprotein (LDL) is normally bound at the cell membrane and taken into the cell ending up in lysosomes where the protein is degraded and the cholesterol is made available for repression of microsomal enzyme 3-hydroxy-3-methylglutaryl coenzyme A (HMG CoA) reductase, the rate-limiting step in cholesterol synthesis. At the same time, a reciprocal stimulation of cholesterol ester synthesis takes place. Mutations in this gene cause the autosomal dominant disorder, familial hypercholesterolemia. Alternate splicing results in multiple transcript variants.[provided by RefSeq, Sep 2010] [NCBI Gene ID:3949]
Source: National Center for Biotechnology Information (NCBI) Gene
Fully-Specified Name
- Component
- LDLR gene full mutation analysis
- Property
- Find
- Time
- Pt
- System
- Bld/Tiss
- Scale
- Doc
- Method
- Sequencing
Additional Names
- Long Common Name
- LDLR gene full mutation analysis in Blood or Tissue by Sequencing
- Short Name
- LDLR gene Full Mut Anl Bld/T Seq
- Display Name
- LDLR gene full mutation analysis Sequencing Doc (Bld/Tiss)
- Consumer Name Alpha Get Info
- LDLR gene variant analysis, Blood or tissue specimen
Associated Observations
81247-9 Master HL7 genetic variant reporting panel
| LOINC | Name | R/O/C | Cardinality | Example UCUM Units |
|---|---|---|---|---|
| 81247-9 | Master HL7 genetic variant reporting panel | |||
| Indent81306-3 | Variables that apply to the overall study | |||
| Indent Indent53577-3 | Reason for study | O | 0..* | |
| Indent Indent51967-8 | Genetic disease assessed [ID] | O | 0..* | |
| Indent Indent51963-7 | Medication assessed [ID] | C | 0..* | |
| Indent Indent48018-6 | Gene studied [ID] | C | 0..* | |
| Indent Indent36908-2 | Gene mutations tested for in Blood or Tissue by Molecular genetics method Nominal | C | 0..* | |
| Indent Indent51959-5 | Range(s) of DNA sequence examined | C | 0..* | |
| Indent Indent81293-3 | Description of ranges of DNA sequences examined | C | 0..1 | |
| Indent Indent51968-6 | Discrete variation analysis overall interpretation | R | 1..1 | |
| Indent Indent83006-7 | Deletion-duplication overall interpretation | C | ||
| Indent Indent51969-4 | Genetic analysis report | O | 0..1 | |
| Indent Indent81291-7 | Variant ISCN | C | ||
| Indent Indent62374-4 | Human reference sequence assembly version | C | 0..1 | |
| Indent Indent81303-0 | HGVS version [ID] | O | 0..1 | |
| Indent Indent82115-7 | dbSNP version [ID] | O | 0..1 | |
| Indent Indent83007-5 | COSMIC version [ID] | O | ||
| Indent Indent83008-3 | ClinVar version [ID] | O | ||
| Indent81250-3 | Discrete genetic variant panel | 0..n | ||
| Indent Indent83005-9 | Variant category | |||
| Indent Indent81252-9 | Discrete genetic variant | C | 0..1 | |
| Indent Indent48018-6 | Gene studied [ID] | C | 0..1 | |
| Indent Indent51958-7 | Transcript reference sequence [ID] | C | 0..1 | |
| Indent Indent48004-6 | DNA change (c.HGVS) | C | 0..1 | |
| Indent Indent48005-3 | Amino acid change (pHGVS) | C | 0..1 | |
| Indent Indent48019-4 | DNA change type | O | 0..1 | |
| Indent Indent48006-1 | Amino acid change [Type] | O | 0..1 | |
| Indent Indent48013-7 | Genomic reference sequence [ID] | C | 0..1 | |
| Indent Indent81290-9 | Genomic DNA change (gHGVS) | C | ||
| Indent Indent69547-8 | Genomic ref allele [ID] | C | 0..1 | |
| Indent Indent81254-5 | Genomic allele start-end | C | 0..1 | |
| Indent Indent69551-0 | Genomic alt allele [ID] | C | 0..1 | |
| Indent Indent84414-2 | Haplotype name | O | ||
| Indent Indent81255-2 | dbSNP [ID] | O | 0..1 | |
| Indent Indent81257-8 | CIGAR [ID] | O | 0..1 | |
| Indent Indent48001-2 | Cytogenetic (chromosome) location | O | 0..1 | |
| Indent Indent48002-0 | Genomic source class [Type] | O | 0..1 | |
| Indent Indent81304-8 | Variant analysis method [Type] | O | ||
| Indent Indent53037-8 | Genetic variation clinical significance [Imp] | O | 0..1 | |
| Indent Indent69548-6 | Genetic variant assessment | O | ||
| Indent Indent81259-4 | Associated phenotype | O | 0..1 | |
| Indent Indent53034-5 | Allelic state | C | 0..1 | |
| Indent Indent81258-6 | Sample variant allelic frequency [NFr] | O | 0..1 | % |
| Indent Indent82121-5 | Allelic read depth | O | 0..1 | {#} |
| Indent Indent82120-7 | Allelic phase | O | 0..1 | |
| Indent Indent82309-6 | Basis for allelic phase [Type] | O | ||
| Indent81297-4 | Structural variant panel | |||
| Indent Indent82155-3 | Genomic structural variant copy number | {#} | ||
| Indent Indent81299-0 | Structural variant reported arrCGH [Ratio] | C | 0..1 | {Ratio} |
| Indent Indent81300-6 | Structural variant [Length] | O | 0..1 | {#} |
| Indent Indent81301-4 | Structural variant outer start and end | O | 0..1 | {Range} |
| Indent Indent81302-2 | Structural variant inner start and end | O | 0..1 | {Range} |
| Indent81251-1 | Complex genetic variant panel | 0..n | ||
| Indent Indent81260-2 | Complex genetic variant [ID] | C | 0..1 | |
| Indent Indent81262-8 | Complex variant HGVS name | C | 0..1 | |
| Indent Indent81263-6 | Complex variant type | C | 0..1 | |
| Indent Indent81259-4 | Associated phenotype | O | 0..1 | |
| Indent Indent53037-8 | Genetic variation clinical significance [Imp] | O | 0..1 | |
| Indent Indent53034-5 | Allelic state | O | 0..1 | |
| Indent Indent82309-6 | Basis for allelic phase [Type] | O | ||
| Indent Indent81250-3 | Discrete genetic variant panel | 0..n | ||
| Indent Indent Indent83005-9 | Variant category | |||
| Indent Indent Indent81252-9 | Discrete genetic variant | C | 0..1 | |
| Indent Indent Indent48018-6 | Gene studied [ID] | C | 0..1 | |
| Indent Indent Indent51958-7 | Transcript reference sequence [ID] | C | 0..1 | |
| Indent Indent Indent48004-6 | DNA change (c.HGVS) | C | 0..1 | |
| Indent Indent Indent48005-3 | Amino acid change (pHGVS) | C | 0..1 | |
| Indent Indent Indent48019-4 | DNA change type | O | 0..1 | |
| Indent Indent Indent48006-1 | Amino acid change [Type] | O | 0..1 | |
| Indent Indent Indent48013-7 | Genomic reference sequence [ID] | C | 0..1 | |
| Indent Indent Indent81290-9 | Genomic DNA change (gHGVS) | C | ||
| Indent Indent Indent69547-8 | Genomic ref allele [ID] | C | 0..1 | |
| Indent Indent Indent81254-5 | Genomic allele start-end | C | 0..1 | |
| Indent Indent Indent69551-0 | Genomic alt allele [ID] | C | 0..1 | |
| Indent Indent Indent84414-2 | Haplotype name | O | ||
| Indent Indent Indent81255-2 | dbSNP [ID] | O | 0..1 | |
| Indent Indent Indent81257-8 | CIGAR [ID] | O | 0..1 | |
| Indent Indent Indent48001-2 | Cytogenetic (chromosome) location | O | 0..1 | |
| Indent Indent Indent48002-0 | Genomic source class [Type] | O | 0..1 | |
| Indent Indent Indent81304-8 | Variant analysis method [Type] | O | ||
| Indent Indent Indent53037-8 | Genetic variation clinical significance [Imp] | O | 0..1 | |
| Indent Indent Indent69548-6 | Genetic variant assessment | O | ||
| Indent Indent Indent81259-4 | Associated phenotype | O | 0..1 | |
| Indent Indent Indent53034-5 | Allelic state | C | 0..1 | |
| Indent Indent Indent81258-6 | Sample variant allelic frequency [NFr] | O | 0..1 | % |
| Indent Indent Indent82121-5 | Allelic read depth | O | 0..1 | {#} |
| Indent Indent Indent82120-7 | Allelic phase | O | 0..1 | |
| Indent Indent Indent82309-6 | Basis for allelic phase [Type] | O | ||
| Indent82118-1 | Pharmacogenomics result panel | |||
| Indent Indent48018-6 | Gene studied [ID] | 1..* | ||
| Indent Indent84413-4 | Genotype display name | |||
| Indent Indent53040-2 | Genetic variation's effect on drug metabolism | C | 0..1 | |
| Indent Indent51961-1 | Genetic variation's effect on drug efficacy | C | 0..1 | |
| Indent Indent83009-1 | Genetic variation's effect on high-risk allele | |||
| Indent Indent82117-3 | Medication usage implications panel | O | 0..* | |
| Indent Indent Indent51963-7 | Medication assessed [ID] | R | 1..* | |
| Indent Indent Indent82116-5 | Medication usage suggestion [Type] | C | 1..1 | |
| Indent Indent Indent83010-9 | Medication usage suggestion [Narrative] | C | ||
| Indent83011-7 | Haplotype definition panel | |||
| Indent Indent48018-6 | Gene studied [ID] | C | 0..1 | |
| Indent Indent84414-2 | Haplotype name | O | ||
| Indent Indent81250-3 | Discrete genetic variant panel | 0..n | ||
| Indent Indent Indent83005-9 | Variant category | |||
| Indent Indent Indent81252-9 | Discrete genetic variant | C | 0..1 | |
| Indent Indent Indent48018-6 | Gene studied [ID] | C | 0..1 | |
| Indent Indent Indent51958-7 | Transcript reference sequence [ID] | C | 0..1 | |
| Indent Indent Indent48004-6 | DNA change (c.HGVS) | C | 0..1 | |
| Indent Indent Indent48005-3 | Amino acid change (pHGVS) | C | 0..1 | |
| Indent Indent Indent48019-4 | DNA change type | O | 0..1 | |
| Indent Indent Indent48006-1 | Amino acid change [Type] | O | 0..1 | |
| Indent Indent Indent48013-7 | Genomic reference sequence [ID] | C | 0..1 | |
| Indent Indent Indent81290-9 | Genomic DNA change (gHGVS) | C | ||
| Indent Indent Indent69547-8 | Genomic ref allele [ID] | C | 0..1 | |
| Indent Indent Indent81254-5 | Genomic allele start-end | C | 0..1 | |
| Indent Indent Indent69551-0 | Genomic alt allele [ID] | C | 0..1 | |
| Indent Indent Indent84414-2 | Haplotype name | O | ||
| Indent Indent Indent81255-2 | dbSNP [ID] | O | 0..1 | |
| Indent Indent Indent81257-8 | CIGAR [ID] | O | 0..1 | |
| Indent Indent Indent48001-2 | Cytogenetic (chromosome) location | O | 0..1 | |
| Indent Indent Indent48002-0 | Genomic source class [Type] | O | 0..1 | |
| Indent Indent Indent81304-8 | Variant analysis method [Type] | O | ||
| Indent Indent Indent53037-8 | Genetic variation clinical significance [Imp] | O | 0..1 | |
| Indent Indent Indent69548-6 | Genetic variant assessment | O | ||
| Indent Indent Indent81259-4 | Associated phenotype | O | 0..1 | |
| Indent Indent Indent53034-5 | Allelic state | C | 0..1 | |
| Indent Indent Indent81258-6 | Sample variant allelic frequency [NFr] | O | 0..1 | % |
| Indent Indent Indent82121-5 | Allelic read depth | O | 0..1 | {#} |
| Indent Indent Indent82120-7 | Allelic phase | O | 0..1 | |
| Indent Indent Indent82309-6 | Basis for allelic phase [Type] | O |
Basic Attributes
- Class
- MOLPATH.MUT
- Type
- Laboratory
- First Released
- Version 2.65
- Last Updated
- Version 2.67 (NAM)
- Change Reason
- Release 2.67: COMPONENT: Corrected order of words in Component for consistency across terms.; Previous Releases: Updated the ORDER_OBS value from "Order" to "Both".
- Order vs. Observation
- Both
Language Variants Get Info
| Tag | Language | Translation |
|---|---|---|
| el-GR | Greek (Greece) | Γονίδιο LDLR πλήρης ανάλυση μεταλλάξεων: Synonyms: Γονίδιο Γονίδιο LDLR Εύρεση |
| es-ES | Spanish (Spain) | Gen LDLR Análisis de mutación completa: |
| es-MX | Spanish (Mexico) | Análisis de mutación completa del gen LDLR: |
| fr-FR | French (France) | LDLR gène complet mutation recherche: |
| it-IT | Italian (Italy) | LDLR, gene Analisi di mutazione completa: Synonyms: Gene LDLR Mutazione genica Osservazione Patologia molecolare Punto nel tempo (episodio) Sangue Sangue o Tessuto Tessuto & |
| nl-NL | Dutch (Netherlands) | LDLR-gen volledige mutatie-analyse: Synonyms: LDLR gen |
| tr-TR | Turkish (Turkey) | LDLR geni tam mutasyon analizi: Synonyms: Dizi tayini |
| zh-CN | Chinese (China) | LDLR 基因 全面突变分析: Synonyms: FH; |
LOINC Terminology Service (API) using HL7® FHIR® Get Info
Requests to this service require a free LOINC username and password. Below is a sample of the possible capabilities. See the LOINC Terminology Service documentation for more information.
- CodeSystem lookup
- https:
//fhir.loinc.org/CodeSystem/$lookup?system=http: //loinc.org&code=90258-5
LOINC Copyright
Copyright © 2025 Regenstrief Institute, Inc. All Rights Reserved. To the extent included herein, the LOINC table and LOINC codes are copyright © Regenstrief Institute, Inc. and the Logical Observation Identifiers Names and Codes (LOINC) Committee. See https://